You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Details for Patent: 11,123,363

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,123,363 protect, and when does it expire?

Patent 11,123,363 protects VELTASSA and is included in one NDA.

This patent has eighteen patent family members in nine countries.

Summary for Patent: 11,123,363

Title:	Potassium-binding agents for treating hypertension and hyperkalemia
Abstract:	The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
Inventor(s):	Klaerner; Gerrit (Los Gatos, CA), Berman; Lance (San Francisco, CA)
Assignee:	VIFOR (INTERNATIONAL) LTD. (St. Gallen, CH)
Application Number:	15/916,617
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 11,123,363

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-001	Oct 21, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF HYPERKALEMIA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,123,363

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013329451	⤷ Sign Up
Australia	2018260862	⤷ Sign Up
Australia	2020294307	⤷ Sign Up
Brazil	112015007749	⤷ Sign Up
Canada	2886788	⤷ Sign Up
China	104822383	⤷ Sign Up
European Patent Office	2916851	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.